FDA Approves Fasenra for Eosinophilic Granulomatosis with Polyangiitis

Approval was based on results from the MANDARA Phase III trial, which demonstrated the superiority of Fansenra over Nucala in patients with eosinophilic granulomatosis with polyangiitis.